Cymabay Therapeutics
CBAY
CBAY was delisted on the 21st of March, 2024.
114 hedge funds and large institutions have $209M invested in Cymabay Therapeutics in 2020 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 31 increasing their positions, 33 reducing their positions, and 24 closing their positions.
136% more capital invested
Capital invested by funds: $88.6M → $209M (+$120M)
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
50% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 24
23% more call options, than puts
Call options by funds: $2.07M | Put options by funds: $1.69M
12% more funds holding
Funds holding: 102 → 114 (+12)
6% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 33
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
+$8.21M |
| 2 |
SCM
Sio Capital Management
New York
|
+$6.25M |
| 3 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
+$4.62M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
+$4.39M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
+$2.99M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECM
Engine Capital Management
New York
|
-$12.9M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$8.01M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$3.11M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
-$2.42M |
| 5 |
JP Morgan Chase
New York
|
-$2.2M |
CBAY Hedge Fund Activity: Q2 2020 in Review
114 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q2 2020, worth a combined $209M — up 136% from $88.6M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new CBAY positions and 24 closed out — a net gain of 12 holders — while 31 added to existing stakes and 33 trimmed.
The largest buyer was Foresite Capital Management IV, opening a new position worth an estimated $8.21M. The largest seller was Engine Capital Management, cutting an estimated $12.9M.
- 114 institutional investors held Cymabay Therapeutics (CBAY) as of Q2 2020, up from 102 in Q1 2020.
- Funds reported $209M of Cymabay Therapeutics stock for Q2 2020, up 136% quarter-over-quarter.
- 36 funds opened new Cymabay Therapeutics positions in Q2 2020 and 24 closed out, a net change of +12 holders.
- The largest Cymabay Therapeutics buyer in Q2 2020 was Foresite Capital Management IV, an estimated $8.21M added.
- The largest Cymabay Therapeutics seller in Q2 2020 was Engine Capital Management, an estimated $12.9M sold.
Based on aggregated 13F filings for Q2 2020.